Loxapine inhalation - Alexza Pharmaceuticals

Drug Profile

Loxapine inhalation - Alexza Pharmaceuticals

Alternative Names: Adasuve; ALXZ-004; AZ-004; Staccato Loxapine

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alexza Pharmaceuticals
  • Developer Alexza Pharmaceuticals; AOP Orphan Pharmaceuticals AG; Ferrer; Galenica S.A.; Teva Pharmaceuticals USA
  • Class Antipsychotics; Dibenzoxazepines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Agitation

Highest Development Phases

  • Marketed Agitation

Most Recent Events

  • 26 Sep 2017 Galen acquires commercial rights in USA for loxapine inhalation powder from Alexza
  • 28 Apr 2017 Loxapine inhalation is no longer licensed to Medivir in Denmark, Finland, Norway, Iceland & Sweden
  • 31 Oct 2016 Ferrer completes a phase III trial for Agitation in Czech Republic, Spain and Germany (EudraCT2014-000456-29)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top